From the original announcement of acceptance of submission:
Acrux has submitted an ANDA application to the FDA for Lidocaine 2.5% and Prilocaine
2.5% cream, which has now been accepted for review
• Annual sales for the product were US$35m as measured by IQVIA 1
• The product is used as a topical anaesthetic
• The announcement marks Acrux’s third product accepted for review by the FDA
So... kinda? Bit of both?
From the original announcement of acceptance of submission:Acrux...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
